Area of Clinical Practice
Treatment of uveal melanoma
Much of my research has involved the development and evaluation of treatment of ocular melanoma, particularly: (1) trans-scleral local resection of choroidal melanoma (personal series of approximately 600 resections, the largest world-wide); (2) endoresection of choroidal melanoma (developed important steps in technique, which are now used elsewhere); (3) proton beam radiotherapy of iris melanoma (world first); (4) resection of ‘toxic tumour’ after radiotherapy (origination of concept and development of surgical treatment).
Current research projects include: (1) The role of tumour stem cells in uveal melanoma development and progression (H. Kalirai); (2) Identification of regulators of metastasis (S. Lake); (3) Molecular characteristics of metastatic liver lesions in uveal melanoma: the search for therapeutic targets (A. Dodson); (4) Comparative digital transcriptional profiling of canine and human uveal melanomas (S. Lake); (5) Proteomic discovery of serum biomarkers in metastatic uveal melanoma (M. Angi); (6) The role of a novel inhibitory isoform of VEGF in ocular melanoma (M. Angi); (7) Gross chromosomal abnormalities in iris melanoma (M. Baudo); (8) TNM staging of ocular adnexal lymphomas (A Javed); (9) TNM staging of uveal melanoma (M. Staunton).
American Academy of Ophthalmology (AAO)
Association for Research in Vision and Ophthalmology (ARVO)
British Eye Study Group 1987-1997 (by invitation)
European Organization for Research and Treatment of Cancer (EORTC)
European Vision and Eye Research (EVER) (Path/Oncol rep 98-00; President 2001)
Int. Soc. of Ocular Oncology (ISOO) (Vice-President, 2007-11; President 2011-date)
Ophthalmic Oncology Group (OOG) (Webmaster, Committee member, 2010-date)
Ophthalmological Society of Alberta (Hon. Fellow)
Royal College of Ophthalmologists
Professor Bertil Damato is a Consultant Ophthalmic Surgeon and Lead Clinician of the Liverpool Ocular Oncology Centre (LOOC), which he established in 1993. He is one of only a handful of eye surgeons specialising exclusively in adult ocular oncology. He has practised in this specialty since 1984. The LOOC receives more than 700 new patients each year, these patients coming from all parts of the British Isles and from overseas. Approximately 250 of these patients have an ocular melanoma, making this centre one of the largest of its kind in the world. LOOC offers a wide range of therapeutic modalities, which include plaque and proton beam radiotherapy, exo- and endoresection, phototherapy and enucleation. It has pioneered and evaluated several novel therapeutic techniques.It is the first to develop personalised prognostication, which is based on genetic typing of melanoma. Clinical research focusses on quality of life, prognostication, MRI screening for metastatic disease and treatment of metastases. The Liverpool Ocular Oncology Research Group (LOORG) performs basic scientific laboratory research on genetic abnormalities of intraocular melanoma. Professor Damato has published approximately 190 scientific articles, several textbook chapters and two books. He lectures extensively around the world. He is currently President of the International Society of Ocular Oncology, Past President of the European Vision and Eye Research organisation and Past President of the European Ophthalmic Oncology Group.
1977 LRCP, MRCS (London)
1982 FRCS (Edinburgh)
1987 PhD (Glasgow)
1989 FRCOphth (UK)
1989 MD (Malta)
Specialised in ocular oncology since 1984. First did a fellowship with Professor
WS Foulds in Glasgow from 1984-1987, inheriting his oncology practice when he
retired in 1989. In 1993, moved to the Royal Liverpool University Hospital, because
of its proximity to the only proton beam unit in the UK and because of its central geographic location in the British Isles.
Director/Clinical Lead of the Liverpool Ocular Oncology Centre (LOOC), which I established at the Royal Liverpool University Hospital in 1993. LOOC receives approximately 700 new patients each year, about 250-300 of these having ocular melanoma (i.e., >4300 since 1993). Patients are referred from all over Britain and Ireland as well as overseas (i.e., >32 countries since 2006). In 1997, LOOC was designated a supra-regional service by the National Specialist Commissioning Advisory Group (NSCAG), which funds almost all our staff and equipment.